Collegium Pharmaceutical (COLL) Amortization of Deferred Charges (2014 - 2026)

Collegium Pharmaceutical has reported Amortization of Deferred Charges for 9 years, with the latest figure at $784000.0 in Q2 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 28.47% year-over-year to $784000.0 in Q2 2026; TTM through Jun 2026 was $4.0 million, a 18.1% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 11.22% from the prior year.
• Amortization of Deferred Charges was $784000.0 for Q2 2026 at Collegium Pharmaceutical, down from $819000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $2.5 million in Q2 2022, with the low at $784000.0 in Q2 2026.
• Average Amortization of Deferred Charges over 5 years is $1.6 million, with a median of $1.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Amortization of Deferred Charges surged 205.91% in 2022, then tumbled 48.0% in 2024.
• Over 5 years, Amortization of Deferred Charges stood at $2.4 million in 2022, then declined by 17.62% to $2.0 million in 2023, then fell by 27.46% to $1.4 million in 2024, then fell by 10.39% to $1.3 million in 2025, then plunged by 38.56% to $784000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $784000.0 (Q2 2026), $819000.0 (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.